Metastatic Prostate Cancer Clinical Trial Pipeline Analysis: 80+ Key Companies Shaping the Future of Metastatic Prostate Cancer Therapeutics | DelveInsight

DelveInsight's Metastatic Prostate Cancer Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline Metastatic Prostate Cancer therapies in various stages of clinical development. The report provides insights into 80+ companies and 85+ pipeline drugs in the Metastatic Prostate Cancer pipeline landscape, covering clinical and nonclinical stage products, therapeutic assessments, and inactive pipeline products.

Key takeaways from the Metastatic Prostate Cancer Clinical Trial Landscape Report

• DelveInsight's Metastatic Prostate Cancer pipeline report depicts a robust space with 80+ companies working to develop 85+ pipeline therapies for Metastatic Prostate Cancer treatment.
• Key Metastatic Prostate Cancer companies such as Telix Pharmaceuticals, Candel Therapeutics, Astellas Pharma, ORIC Pharmaceuticals, Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Geode Therapeutics Inc, Cullgen, AstraZeneca, TYK Medicines, Inc., K36 Therapeutics, Inc., Bristol-Myers Squibb, Kyntra Bio, ARTBIO Inc., Acerand Therapeutics, Janux Therapeutics, Evopoint Biosciences Inc., AbbVie, Arsenal Biosciences, Inc., Fusion Pharmaceuticals Inc., and others.
• Promising Metastatic Prostate Cancer pipeline therapies in various stages of development include TLX591, CAN-2409, ASP5541, ORIC-944, RO7656594, TQB3201, GT-220F, Epigenetic Factor, AZD9750, TYK-00540, KTX-2001, BMS-986460, FG-3246, AB001, ACE-232, JANX007, XNW5004, ABBV-969, AB-3028, FPI-2265, and others.

Request a sample and discover the recent advances in Metastatic Prostate Cancer treatment drugs https://www.delveinsight.com/sample-request/metastatic-prostate-cancer-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

What is Metastatic Prostate Cancer?

Metastatic prostate cancer (MPC) is an advanced form of Prostate Cancer in which malignant cells spread from the prostate gland to distant organs, most frequently the bones, lymph nodes, liver, and lungs. It represents stage IV disease and is often categorized into stage IVA and stage IVB. Initially, many patients develop metastatic hormone-sensitive prostate cancer (mHSPC), which responds to androgen deprivation therapy (ADT).
Over time, the disease may progress to metastatic castration-resistant prostate cancer (mCRPC) despite low testosterone levels, making it more aggressive and difficult to treat. Bone metastases occur in more than 70% of patients, while visceral metastases are seen in fewer than 30%. Survival varies depending on disease burden, reaching about 92 months in low-volume disease but dropping to roughly 55 months in high-volume cases.
Diagnosis relies on PSA monitoring, imaging techniques, and biopsy confirmation once the disease spreads beyond the prostate. Conventional imaging methods such as bone scans, CT, and MRI are commonly used, while advanced molecular imaging techniques, particularly PSMA-PET/CT, offer higher sensitivity for detecting metastatic sites.
Treatment of metastatic prostate cancer has increasingly shifted toward intensified systemic therapy strategies. Androgen deprivation therapy remains the backbone of treatment and is typically combined with androgen receptor pathway inhibitors such as Abiraterone, Enzalutamide, Apalutamide, or Darolutamide. Chemotherapy, targeted therapy, and radioligand therapy may also be used depending on disease stage, prior treatment exposure, and molecular characteristics.

Emerging Metastatic Prostate Cancer Drug Profiles

TLX591: Telix Pharmaceuticals
TLX591 is an investigational radio antibody-drug conjugate (rADC) being developed for the treatment of metastatic castration-resistant Prostate Cancer (mCRPC). The therapy consists of a highly specific PSMA-targeting monoclonal antibody linked through a chelator to the radioactive isotope lutetium-177 (177Lu), enabling targeted delivery of radiation to prostate cancer cells expressing PSMA.
Administered intravenously in a two-dose fractionated regimen, the approach is designed to deliver a potent and localized radiation dose while minimizing exposure to healthy organs. TLX591 is currently being evaluated in Phase III clinical development for the treatment of metastatic prostate cancer.

CAN-2409: Candel Therapeutics

CAN-2409 is an investigational gene-mediated immunotherapy being developed for the treatment of metastatic prostate cancer (MPC). The therapy uses a replication-deficient adenoviral vector to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene directly into tumor cells. Following administration of an antiviral prodrug such as Valacyclovir, the modified tumor cells convert the drug into a toxic metabolite, leading to selective cancer cell death.
This process also stimulates a systemic immune response against tumor antigens, potentially enhancing antitumor activity beyond the treated site. The drug is currently being evaluated in Phase III clinical development for metastatic prostate cancer.

ASP5541: Astellas Pharma

ASP5541 is an investigational small-molecule therapy being explored for the treatment of metastatic prostate cancer. The drug functions as a selective androgen receptor (AR) antagonist designed to inhibit androgen-mediated signaling that drives tumor growth and progression. By blocking activation of the androgen receptor, ASP5541 aims to suppress prostate cancer cell proliferation even in advanced or treatment-resistant disease.
ASP5541 is being evaluated in Phase II clinical trials for the treatment of advanced prostate cancer.
Learn more about the novel and emerging Metastatic Prostate Cancer pipeline therapies https://www.delveinsight.com/sample-request/metastatic-prostate-cancer-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Scope of the Metastatic Prostate Cancer Pipeline Report

• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Phase III, Phase II, Phase I, Preclinical, Discovery
• Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical
• Therapeutics Assessment By Molecule Type: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy
• Key Metastatic Prostate Cancer Companies: Telix Pharmaceuticals, Candel Therapeutics, Astellas Pharma, ORIC Pharmaceuticals, Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Geode Therapeutics Inc, Cullgen, AstraZeneca, TYK Medicines, Inc., K36 Therapeutics, Inc., Bristol-Myers Squibb, Kyntra Bio, ARTBIO Inc., Acerand Therapeutics, Janux Therapeutics, Evopoint Biosciences Inc., AbbVie, Arsenal Biosciences, Inc., Fusion Pharmaceuticals Inc.
• Key Metastatic Prostate Cancer Pipeline Therapies: TLX591, CAN-2409, ASP5541, ORIC-944, RO7656594, TQB3201, GT-220F, Epigenetic Factor, AZD9750, TYK-00540, KTX-2001, BMS-986460, FG-3246, AB001, ACE-232, JANX007, XNW5004, ABBV-969, AB-3028, FPI-2265.

Dive deep into rich insights for new drugs for Metastatic Prostate Cancer treatment, visit https://www.delveinsight.com/sample-request/metastatic-prostate-cancer-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents

1. Metastatic Prostate Cancer Pipeline Report Introduction
2. Metastatic Prostate Cancer Pipeline Report Executive Summary
3. Metastatic Prostate Cancer: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Metastatic Prostate Cancer Pipeline Therapeutics
6. Metastatic Prostate Cancer Pipeline: Late Stage Products (Phase III)
7. Metastatic Prostate Cancer Pipeline: Mid Stage Products (Phase II)
8. Metastatic Prostate Cancer Pipeline: Early Stage Products (Phase I)
9. Metastatic Prostate Cancer Pipeline: Preclinical and Discovery Stage Products
10. Metastatic Prostate Cancer Pipeline Therapeutics Assessment
11. Inactive Products in the Metastatic Prostate Cancer Pipeline
12. Key Companies
13. Key Products in the Metastatic Prostate Cancer Pipeline
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

For further information on the Metastatic Prostate Cancer pipeline therapeutics, reach out https://www.delveinsight.com/sample-request/metastatic-prostate-cancer-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Media Contact
Company Name: DelveInsight
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +1-469-945-7679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, DelveInsight offers customized research solutions and insights to clients across the globe.

This release was published on openPR.